Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• SM and other types of mastocytosis are more common than previously reported

  Improved diagnostics resulted in a higher prevalence of mastocytosis, including SM, than earlier reported, a new study said.

• Avapritinib improved survival and treatment duration in advanced SM

  Avapritinib significantly improved overall survival in patients with SM compared to midostaurin or best available therapy.

• RNA analysis more sensitive in detecting KIT mutation in SM diagnosis: study

  RNA-based testing significantly enhanced the detection of KIT mutations, which is critical for diagnosing systemic mastocytosis.

• Bezuclastinib shows promise in treating nonadvanced systemic mastocytosis

  A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.

• Women with indolent SM had greater quality of life challenges than men, study says

  More than half of patients with indolent systemic mastocytosis reported mild or worse quality of life issues.

• New study clarifies allergy and anaphylaxis risks in patients with mastocytosis

  Mastocytosis increased the risk of venom-induced anaphylaxis, but food and drug allergies were often overreported.

• Nasal epinephrine powder shows promise in emergency SM allergy treatment: company

  Intranasal epinephrine powder’s rapid absorption makes it a promising alternative to traditional epinephrine injections, a company said.

• GI monitoring is crucial for patients with SM, new study says

  Vigilant monitoring of gastrointestinal health is crucial for patients with systemic mastocytosis to avoid complications, a new study finds.